Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer : Alexandra Leary.
BMC Cancer
; 24(1): 911, 2024 Jul 29.
Article
in En
| MEDLINE
| ID: mdl-39075404
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
BMC Cancer
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Affiliation country:
France
Country of publication:
United kingdom